Q&A: New Rules for Clinical Trials conducted in the EU
Recommendation
4-6 March 2025
Management, Supply and Quality Assurance of Clinical Trials
Following the positive vote in Parliament for the new Clinical Trial Regulation, the EU Commission has published a set of Q&As on clinical trials.
Here it is also discussed why the current legislation is being replaced and the main changes are summarised:
- The new authorisation procedure
- The simplified reporting procedures
- More rights for the Commission to conduct controls
In the new regulation, the concept of tacit agreement in the assessment phase of an application will be extended. According to the Q&A, this was needed "to avoid bottlenecks and delays in the procedure".
Related GMP News
20.01.2025Final ICH E6(R3) Guideline on GCP released
14.01.2025Swissmedic Position Paper on Clinical Trials
14.01.2025Annual Report of the GCP Inspectors' Working Group
05.12.2024ICH E6(R3) Annex 2 Draft Guideline Released
05.12.2024ICH M15 Draft Guideline on Model-Informed Drug Development
07.11.2024Interim-Report on EMA's Clinical Study Data Proof-of-Concept Pilot